- Hezbollah chief admits 'unprecedented' blow in device blasts
- Sales of US existing homes slip slightly in August
- Fear, panic haunt Lebanese after devices explode
- Labuschagne sparks Australia fightback in England ODI opener
- S.Africa's HIV research power couple says fight goes on
- Why is Israel focusing on border with Lebanon?
- Mpox vaccines administered in Rwanda, first in Africa
- US Fed rate cut is 'very positive sign' for economy: Yellen
- Unknown Mozart string trio discovered in Germany
- 'Are we five-year-olds?' F1 drivers won't mind their language
- Brazil judge orders X to reimpose block or face hefty fine
- Munich to rename stadium street after Beckenbauer
- Champions Italy to face Argentina in Davis Cup Final 8
- The winding, fitful path to weight loss drug Ozempic
- Italians defeat American Magic to reach Louis Vuitton Cup final
- Norris has 'nothing to lose' as he hunts Verstappen in Singapore
- Kyiv 'outraged' at Swiss showing of Russian war film
- French city renames Abbe Pierre square after abuse claims
- Footballer charged after huge cannabis seizure at UK airport
- Vatican recognises Medjugorje shrine, but not Virgin's messages
- Israel bombs Hezbollah strongholds in Lebanon after wave of deadly blasts
- Bank of England freezes rate after jumbo US cut
- Playing Nadal is 'kind of a nightmare', says Alcaraz
- Portugal tackles last of deadly northern forest fires
- Ton-up Ashwin lifts India to 339-6 against Bangladesh
- Departing NATO chief warns US against 'isolationism'
- Coming winter 'sternest test yet' for Ukraine energy grid
- Evacuations as tail of Storm Boris floods northeast Italy
- Lebanon's Hezbollah reeling after second wave of deadly blasts
- Taiwan recognises same-sex marriages between Chinese, Taiwanese
- Stock markets rally after jumbo US rate cut
- Gabon's ousted leader Bongo says renouncing politics for good
- Lebanon device blasts: what we know about deadly attacks
- Equity markets rally after jumbo US rate cut
- Late Harrods owner Al-Fayed accused of rape: BBC
- Hong Kong man sentenced 14 months for wearing 'seditious' T-shirt
- Lebanon's Hezbollah in disarray after second wave of deadly blasts
- Equity markets, yen rally after jumbo US rate cut
- Meta and Spotify blast EU decisions on AI
- Hasan takes three as Bangladesh rattle India in first Test
- Two killed during police operation in New Caledonia
- Flood-hit region leaders to meet in Poland to discuss EU aid
- Sri Lanka to vote in first poll since economic collapse
- Hong Kong probe finds Cathay Airbus defect could cause 'extensive' damage
- AI development cannot be left to market whim, UN experts warn
- All Blacks primed for 'hell' of a Wallabies clash
- Japan firm says no longer makes radio reportedly used in Lebanon blasts
- Zoom fatigue? Try some nature in your background: study
- Boeing to start large-scale furloughs with Seattle strike talks stalled
- Japan walkie-talkie maker says investigating after Lebanon blasts
BCC | 3.88% | 142.595 | $ | |
CMSD | 0.12% | 25.01 | $ | |
BCE | -0.42% | 35.46 | $ | |
RIO | 3.57% | 65.24 | $ | |
RBGPF | 5.79% | 60.5 | $ | |
NGG | -2.09% | 68.615 | $ | |
SCS | -6.97% | 13.19 | $ | |
CMSC | -0.18% | 25.01 | $ | |
RYCEF | 5.35% | 6.92 | $ | |
RELX | 1.26% | 47.975 | $ | |
JRI | -0.41% | 13.385 | $ | |
VOD | -1.78% | 10.051 | $ | |
GSK | -1.16% | 41.945 | $ | |
AZN | 0.52% | 78.99 | $ | |
BP | 2.22% | 33.165 | $ | |
BTI | -0.76% | 37.595 | $ |
Adding peanuts to young children's diet can help avoid allergy: study
Including peanuts in children's diets early in life could help stave off allergies against the legume, which can be fatal and affect swathes of youngsters globally, according to a new study Friday.
Researchers found that introducing peanut products to babies and infants, and gradually increasing exposure, led to greater tolerance for the common allergen.
The peer-reviewed study, published in The Lancet, involved 146 peanut-allergic children aged between zero and three over two-and-a-half years.
Of the group, 96 were given peanut protein powder every day, with the dose increasing progressively to the equivalent of six peanuts. The other children received a placebo of oat flour.
Twenty of the children who received peanut powder showed allergy remission, meaning no allergic reaction occurred six months after the therapy ended.
One child in the placebo group showed remission.
Six months after the treatment, the children in remission could tolerate a dose equivalent to 16 peanuts.
An additional 20 children who received peanut powder were considered 'desensitised', meaning they had a higher allergic threshold but were not considered in remission.
These children could tolerate a dose equivalent to between six and 12 peanuts six months after the treatment ended.
The youngest children in the study experienced remission the most often, and the best results were in those under 12 months.
"Very early interventions may provide the best opportunity to achieve remission", said co-author Stacie Jones.
- 'Considerable burden' -
Peanut allergies affect two percent of children in Western countries, according to the study, and can last a lifetime.
Affected children must avoid eating peanuts and have self-injectable adrenaline available to fight allergic shocks, which can be fatal if they are accidentally exposed.
Exposure can even occur when a child hugs someone who has just consumed peanuts.
"There are no treatment options, resulting in a considerable burden on allergic children and their caregivers to avoid accidental exposure," said co-author Wesley Burks.
"In severe cases, this can restrict peanut-allergic children's freedoms, particularly when it comes to navigating daycare or schools and public spaces where access to a safe diet is in jeopardy," he added.
Previous studies have produced similar results but the length of the latest studies makes it unique.
Although it provided important results, it may not reflect the behaviour of the children's bodies in real-world conditions.
The study was conducted under close medical supervision, and adrenaline injections were administered on 21 children during the trial.
O.Lorenz--BTB